Now Playing
|Videos|October 11, 2016
CASE 4: 52-Year-Old Man with Relapsed Metastatic NSCLC
Advertisement
Episodes in this series
Jonathan W. Riess, MD, MS:
Riess case 4:
52-year-old man with relapsed metastatic NSCLC.
- 52-year-old man developed NSCLC, metastatic to the bone and brain
- Was found to have an EGFR activating mutation
- Started on erlotinib with a good response, received radiotherapy to hip and brain
- After 12 months he developed cough and dyspnea on exertion
- CT scan showed progression in the primary lesion and multiple other pulmonary nodules
- Tissue biopsy showed an EGFR T790M mutation
- Subsequent treatment with osimertinib resulted in tumor shrinkage as well as resolution of his symptoms.
Advertisement
Related to this article
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5